Previous 10 | Next 10 |
BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective imme...
Quick Take Forma Therapeutics Holdings ( FMTX ) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement. The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers. FMTX...
Canadian biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) is undergoing a transformation. The company is embarking on a rare opportunity to deliver the first U.S. Food and Drug Administration (FDA) approved therapy for the treatment of lupus nephritis (LN), a serious inflammation of the kidn...
Global Blood Therapeutics (NASDAQ: GBT ) +4.8% after-hours, saying it plans to ask the Food and Drug Administration to allow expanded use of its Oxbryta sickle cell treatment in children aged 4-11 years, expanding on an earlier approval for patients 12 and over. More news on: Glob...
New Drug Application submission, including new age-appropriate formulation, planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced plans to expand the potential use of Oxbryta ® ...
SOUTH SAN FRANCISCO, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020, at 3:50 p.m. Eastern Time. The present...
Sickle cell anemia is a genetic disorder that reduces the capacity of red blood cells to deliver oxygen to organs across the body. The disease is estimated to affect more than 100,000 Americans and has a market opportunity worth $3.68 billion on a global scale. Last year, the Food and Dru...
Developing novel drugs for unmet medical needs remains the mission for many emerging drug developers. These pharma companies tackle a range of diseases but have one common attribute. Healthcare investors can look past the development risk. Two companies have approved drugs recently launched in...
Data include retrospective analysis of landmark STOP 2 Study highlighting correlation between higher hemoglobin levels and lower transcranial Doppler (TCD) flow velocities in children with sickle cell disease SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Global Blood T...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...